INSM Reports Positive Phase 3b ENCORE Study Topline: 590mg ARIKAYCE + azithromycin/ethambutol 3.11 pts Resp Score Δ, 30.8% Culture Conv Δ, p<0.0001; Plans sNDA filing H2 2026, PMDA submission, Investor Call Mar 23 8 AM ET
Insmed, Inc. · PHARMACEUTICAL PREPARATIONS · Now $106.03
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS